GenoScreen
Meet us at in-cosmetics® global
GenoScreen will participate in in-cosmetics® global from June 30 to July 2, 2020, in Barcelona, Spain.
The beneficial impact of probiotic yeast S. boulardii CNCM I-745 on hypercholesterolemia is associated with modulation of the intestinal microbiota
A new study evaluated the impact of probiotic yeast S. boulardii CNCM I-745 on lipid profile in a hypercholesterolemia model in hamsters, combining analyses of intestinal microbial communities carried out via our Metabiote solutions.
Meet us at the 6th edition of NutrEvent
GenoScreen will participate in the 6th edition of NutrEvent on October 22 and 23 in Rennes, France.
Re-launch of targeted metagenomics training
Targeted metagenomics training (theoretical and practical): "Analytical approach for the high throughput study of microbial communities" is now back on the agenda
Meet us at the 8th Congress of European Microbiologists
GenoScreen will participate in the 8th Congress of European Microbiologists from 7-11 July in Glasgow, Scotland.
Meet us at these next events:
During June and July 2019, the GenoScreen team will attend several exhibitions and conferences:
Meet us at the 8th Symposium on Antimicrobial Resistance in Animals and the Environment.
GenoScreen is a sponsor of the 8th Symposium on Antimicrobial Resistance in Animals and the Environment (ARAE) from July 1 to 3 in Tours Val de Loire.
Subcategories
Partners
At GenoScreen, our genomics expertise is built on collaboration with a dense network of scientific, industrial and institutional partners. These partnerships strengthen our ability to innovate, co-develop new technologies and advance research in molecular microbiology.
A network of strategic partners
We actively collaborate with:
Research institutes, universities and hospitals
Competitive clusters specialized in biotechnology and healthcare
Public funding bodies
A co-development strategy
Our research projects are carried out with recognized partners in France and abroad. Together, we can :
- Co-develop innovative genomics and bioinformatics solutions
- Reply to national and international applications for projects (Horizon Europe, ANR, etc.)
- Test and validate our technologies in a variety of environments
- Launch the implementation of concrete solutions for health, agriculture and the environment
Why collaborate with GenoScreen?
- Access to an innovative sequencing technology platform
- Access to recognized expertise in bioinformatics analysis and biomarkers
- Benefit from our ability to manage collaborative R&D projects
- Strive for health, agriculture and environment
Join our network of partners
Do you represent a company, laboratory or public body? Contact us to discuss a collaboration or partnership.
Frequently asked questions
What kind of partners work with GenoScreen?
GenoScreen works with academic laboratories, biotech companies and clusters.
What are the benefits of these partnerships?
They help us co-develop technologies, co-finance projects and accelerate innovation.
How can I propose a partnership?
You can contact us via our contact form to discuss your project and identify a potential collaboration.
Collaborative research - At the heart of international innovation in genomics
GenoScreen is a partner in collaborative research projects that bring together startups, multinationals and public-sector organizations. Our R&D teams provide their knowledge and expertise in the molecular microbiology of isolated agents and complex communities. This allowed our teams to develop our own projects for elaborating innovative products and services.
Our projects are designed to:
- Improve the diagnosis and management of acute/chronic diseases on humans and animals,
- Characterize and monitor microbial biodiversity, with applications in agronomy, agrifood and environment.
The common feature of these projects is the development of molecular tools for the characterization, monitoring and diagnosis of microbial communities. The key objective is to market simple analytical solutions and (ultimately) preventive, corrective or even therapeutic products based on microorganisms.